Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Apr:93:19-27.
doi: 10.1016/j.ejca.2018.01.072. Epub 2018 Feb 12.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

X Pivot  1 , I Bondarenko  2 , Z Nowecki  3 , M Dvorkin  4 , E Trishkina  5 , J-H Ahn  6 , S-A Im  7 , T Sarosiek  8 , S Chatterjee  9 , M Z Wojtukiewicz  10 , Y Shparyk  11 , V Moiseyenko  12 , M Bello 3rd  13 , V Semiglazov  14 , Y Lee  15 , J Lim  15
Affiliations
Free article
Clinical Trial

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

X Pivot et al. Eur J Cancer. 2018 Apr.
Free article

Abstract

Background: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment.

Patients and methods: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide). Patients then underwent surgery, followed by 10 cycles of adjuvant SB3 or TRZ as randomised. End-points included safety, immunogenicity, event-free survival (EFS) and overall survival through the adjuvant period.

Results: Of 875 patients randomised, 764 (SB3, n = 380; TRZ, n = 384) completed the study. The median follow-up duration was 437 days in the SB3 group and 438 days in the TRZ group. The incidence of treatment-emergent adverse events was comparable between groups (SB3, 97.5%; TRZ, 96.1%) during the overall study period. Up to the end of study, the overall incidence of antidrug antibody was low in both treatment groups (3 patients each). EFS was comparable between groups with a hazard ratio (SB3/TRZ) of 0.94 (95% confidence interval, 0.59-1.51) and EFS rates at 12 months of 93.7% for SB3 and 93.4% for TRZ.

Conclusions: Final safety, immunogenicity and survival results of this study further support the biosimilarity established between SB3 and TRZ.

Trial registration: ClinicalTrials.gov (NCT02149524); EudraCT (2013-004172-35).

Keywords: Biosimilar; Early breast cancer; Event-free survival; HER2; Safety; Trastuzumab.

PubMed Disclaimer

Comment in

Publication types

MeSH terms

Associated data